Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

Good points Nidan. The next shoe to

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
polarbear77 Member Profile
 
Followed By 13
Posts 802
Boards Moderated 0
Alias Born 12/12/16
160x600 placeholder
Anavex Life Sciences Issued New U.S. Patent for ANAVEX®2-73 Treatment of Neurodevelopmental Disorders including Rett Syndrom... GlobeNewswire Inc. - 1/8/2020 7:00:10 AM
Anavex Life Sciences Reports Fiscal Year 2019 Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 12/16/2019 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019 GlobeNewswire Inc. - 12/10/2019 7:00:10 AM
Citation Growth Corp. (OTCQX: CGOTF) Weathering the Cannabis Downturn InvestorsHub NewsWire - 12/9/2019 7:23:11 AM
Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer's Disease (CTAD) 2019 Con... GlobeNewswire Inc. - 12/4/2019 7:00:10 AM
Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment o... GlobeNewswire Inc. - 11/14/2019 7:00:00 AM
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome GlobeNewswire Inc. - 11/6/2019 7:00:00 AM
Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease GlobeNewswire Inc. - 10/9/2019 7:00:00 AM
Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’... GlobeNewswire Inc. - 10/2/2019 7:00:00 AM
Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from th... GlobeNewswire Inc. - 9/27/2019 3:00:00 AM
Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire Inc. - 9/26/2019 7:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/23/2019 6:35:19 AM
Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference GlobeNewswire Inc. - 9/18/2019 7:00:00 AM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 9/17/2019 5:16:10 PM
CLS Holdings (CLSH) $1.15 Price Target - MASS Approval for Recreational License InvestorsHub NewsWire - 9/17/2019 7:17:00 AM
Withdrawal of Registration Statement (ammendment) (aw) Edgar (US Regulatory) - 9/16/2019 4:17:42 PM
Anavex Life Sciences Announces Preliminary Clinical Efficacy Data of its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patie... GlobeNewswire Inc. - 9/16/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/13/2019 5:11:08 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 9/13/2019 5:07:24 PM
Securities Registration Statement (simplified Form) (s-3/a) Edgar (US Regulatory) - 9/13/2019 5:02:44 PM
Anavex Life Sciences to Present at the Janney Healthcare Conference 2019 GlobeNewswire Inc. - 9/5/2019 7:00:00 AM
Anavex Life Sciences Announces Initiation of the EXCELLENCE ANAVEX®2-73-RS-003 Clinical Study in Pediatric Patients with Ret... GlobeNewswire Inc. - 9/4/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/7/2019 4:07:28 PM
Anavex Life Sciences Reports Fiscal 2019 Third Quarter Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 8/7/2019 7:00:00 AM
Anavex Life Sciences to Announce Fiscal 2019 Third Quarter Financial Results on Wednesday, August 7th, 2019 GlobeNewswire Inc. - 8/2/2019 7:00:00 AM
polarbear77   Wednesday, 08/28/19 12:40:50 PM
Re: nidan7500 post# 207562
Post # of 231002 
Good points Nidan. The next shoe to drop will seemingly be the deep dive peer-reviewed publication on our ph2a AD results that Dr M referenced at our annual meeting.

We can then add that upcoming medical journal to other recent events including:

• today’s robust & positive S1R publication in Frontiers (which references 2-73 and 3-71 specifically); and factor in all of the other recent positives including

• our new CMO in 2019 Dr Kaufmann (Rett Syndrome leading researcher),

• key job postings at indeed.com last week,

• our 2019 announced ERP Biomarker consortium with BP and Cognision

• our leadership role in precision medicine in the CNS space,

• Rett Syndrome trial DSMB review outcome received as a positive sign (per Janney Montgomery Scott analyst Yun Zhong),

• purchase of $1MM of 2-73 inventory

• “we are working with specialists” to develop a commercial name for 2-73 Blarcamesine,

• RS and PDD and AD researchers/participants asking to extend treatment in current trials and the ph2a trial,

• 4-5 years of safety with generally mild AE (indicative of compound crossing the BBB per Dr M)

• positive reported RWE in ph2a, as referenced in presentations and trial PI Macfarlane media quotes

• AD promising-efficacy especially when dose/blood concentration correlated per Ariana analysis

• according to q3 conf call, the Company believes (awaiting confirmation in current trials) that 2-73/blarcamesine is able to correlate with an improvement in gut microbiata levels (patients had a higher diversity in the gut)

Are US regulators being made aware of Anavex’s progress & the growing body of scientific support for our MOA across a WIDE RANGE of debilitating medical diseases and conditions??

If so, and in light of our long-term safety record and mild side effects and positive real world evidence, combined with the need to treat AD at the earliest stage possible, HOW/WHY are we not yet granted an accelerated approval pathway by the US Food & Drug Administration?

Where is the contradictory scientific evidence negating our MOA?

I can only find solid SUPPORT.

To invoke the great philosopher Michael Stipe from REM, it seems we are pushing an elephant up the stairs.

Pressure is building though, and it’ll likely come from the outside. Our trial patients/caregivers and trial PI’s & S1R worldwide researchers’ influence may someday tilt the scale.


https://www.frontiersin.org/articles/10.3389/fnins.2019.00862/full?utm_source=F-NTF&utm_medium=EMLX&utm_campaign=PRD_FEOPS_20170000_ARTICLE

Jobs at Anavex, driven by innovation, problem-solving and fast growth vision:https://www.indeed.com/jobs?q=anavex&l=

https://erpbiomarkers.org/

https://www.nasdaq.com/aspx/call-transcript.aspx?StoryId=4282937&Title=anavex-life-sciences-avxl-ceo-christopher-missling-on-q3-2019-results-earnings-call-transcript

https://www.frontiersin.org/articles/10.3389/fimmu.2018.02325/full#h2

[https://www.google.com/amp/s/finance.yahoo.com/amphtml/news/congress-big-pharma-money-123757664.html
“I’m really much more concerned because Congress is supposed to have oversight for the FDA,” Brown said. “If the FDA isn’t going to hold pharma accountable, and Congress is getting paid to not hold pharma accountable, then it really doesn’t matter who the president is because it’s really about Congress.”]



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist